title: Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors.
abstract: PURPOSEl: Childhood cancer survivors treated with anthracyclines and cardiac radiation are at risk for late-onset cardiotoxicity. The purpose of this study was to delineate the relationship between clinical factors and abnormalities of noninvasive cardiac testing (NICT).
  
  
  METHODS
  Participants were recruited from a long-term follow-up clinic. Study measures comprised physical examination, laboratory evaluation, echocardiogram, and ECG. Mean fractional shortening (FS) and afterload were compared for survivors who did (at risk [AR]) and did not (no risk [NR]) receive potentially cardiotoxic modalities, and with values expected for comparable age- and sex-matched controls.
  
  
  RESULTS
  The 278 study participants (mean age, 18.1 years; median age, 16.8 years; range, 7.5 to 39.7 years) included 223 survivors AR for cardiotoxicity after treatment with anthracyclines (median dose +/- standard deviation [SD], 202 +/- 109 mg/m(2)) and/or cardiac radiation. Mean FS (+/- SD) was lower for AR (0.33 +/- 0.06) compared with NR survivors (0.36 +/- 0.05; P = .004) and normative controls (0.36 +/- 0.04; P < .001). Mean afterload (+/- SD) was higher for AR (58 +/- 21 g/cm(2)) compared with NR survivors (46 +/- 15 g/cm(2); P < .001) and normative controls (48 +/- 13 g/cm(2); P < .001). The distribution of FS and afterload among NR survivors did not differ from that of controls. After adjustment for age group at diagnosis and time since completion of therapy, anthracycline dose predicted decline in distribution of FS (P < .001) and increase in distribution of afterload (P < .001). Treatment with anthracycline doses >or= 100 mg/m(2) increased the risk of abnormal NICT; survivors who received >or= 270 mg/m(2) had a 4.5-fold excess risk of abnormal NICT (95% CI, 2.1 to 9.6) compared with controls.
  
  
  CONCLUSIONS
  Childhood cancer survivors treated with anthracycline doses >or= 270 mg/m(2) are at greatest risk for abnormalities of FS and afterload.
authors: Department of Hematology Oncology, Division of Behavioral Medicine, St Jude Children's Research Hospital, the University of Tennessee, College of Medicine, Memphis, TN 38105, USA. melissa.hudson@stjude.org
authors: Melissa M
authors: MM
authors: Hudson
authors: Shesh N
authors: SN
authors: Rai
authors: Cesar
authors: C
authors: Nunez
authors: Thomas E
authors: TE
authors: Merchant
authors: Neyssa M
authors: NM
authors: Marina
authors: Nia
authors: N
authors: Zalamea
authors: Cheryl
authors: C
authors: Cox
authors: Sean
authors: S
authors: Phipps
authors: Ronald
authors: R
authors: Pompeu
authors: David
authors: D
authors: Rosenthal
mesh_terms: D018943:Anthracyclines / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002675:Child, Preschool; D004452:Echocardiography; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006321:Heart / Q000187:drug effects*; D006333:Heart Failure / Q000139:chemically induced / Q000175:diagnosis; D006334:Heart Function Tests; D006801:Humans; D007223:Infant; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents